Cullinan Therapeutics Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
109
- Stock Symbol
-
CGEM
- Investments
-
2
- Share Price
-
$8.89
- (As of Friday Closing)
Cullinan Therapeutics General Information
Description
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Contact Information
Website
www.cullinantherapeutics.comCorporate Office
- 1 Main Street
- Suite 1350
- Cambridge, MA 02142
- United States
Corporate Office
- 1 Main Street
- Suite 1350
- Cambridge, MA 02142
- United States
Cullinan Therapeutics Stock Performance
As of 20-Nov-2026, Cullinan Therapeutics’s stock price is $8.89. Its current market cap is $577M with 64.9M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $8.89 | $9.07 | $8.47 - $23.19 | $577M | 64.9M | 993K | -$3.08 |
Cullinan Therapeutics Financials Summary
As of 30-Sep-2026, Cullinan Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 655,378 | 280,031 | 133,580 | (24,580) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (218,825) | (241,780) | (196,812) | (190,540) |
| Net Income | (203,466) | (219,879) | (167,383) | (153,162) |
| Total Assets | 322,559 | 448,374 | 621,824 | 484,182 |
| Total Debt | 2,004 | 2,683 | 2,151 | 3,590 |
Cullinan Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Cullinan Therapeutics Comparisons
Industry
Financing
Details
Cullinan Therapeutics Competitors (57)
One of Cullinan Therapeutics’s 57 competitors is ORIC Pharmaceuticals, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ORIC Pharmaceuticals | Formerly VC-backed | South San Francisco, CA | ||||
| Aura Biosciences | Formerly VC-backed | Boston, MA | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| Geron | Formerly VC-backed | Foster City, CA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA |
Cullinan Therapeutics Signals
Cullinan Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Cullinan Therapeutics Investments (2)
Cullinan Therapeutics’s most recent deal was a Secondary Transaction - Private with Cullinan Mica for . The deal was made on 25-Oct-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Cullinan Mica | 25-Oct-2022 | Secondary Transaction - Private | Drug Delivery | ||
| Cullinan Mica | 11-Jun-2020 | Later Stage VC | Drug Delivery |
Cullinan Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
37.73 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Cullinan Therapeutics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Cullinan Pearl | Cambridge, MA |
Cullinan Therapeutics FAQs
-
When was Cullinan Therapeutics founded?
Cullinan Therapeutics was founded in 2016.
-
Where is Cullinan Therapeutics headquartered?
Cullinan Therapeutics is headquartered in Cambridge, MA.
-
What is the size of Cullinan Therapeutics?
Cullinan Therapeutics has 109 total employees.
-
What industry is Cullinan Therapeutics in?
Cullinan Therapeutics’s primary industry is Drug Discovery.
-
Is Cullinan Therapeutics a private or public company?
Cullinan Therapeutics is a Public company.
-
What is Cullinan Therapeutics’s stock symbol?
The ticker symbol for Cullinan Therapeutics is CGEM.
-
What is the current stock price of Cullinan Therapeutics?
As of 20-Nov-2026 the stock price of Cullinan Therapeutics is $8.89.
-
What is the current market cap of Cullinan Therapeutics?
The current market capitalization of Cullinan Therapeutics is $577M.
-
Who are Cullinan Therapeutics’s competitors?
ORIC Pharmaceuticals, Aura Biosciences, Ayala Pharmaceuticals, Geron, and Kite Pharma are some of the 57 competitors of Cullinan Therapeutics.
-
What is Cullinan Therapeutics’s annual earnings per share (EPS)?
Cullinan Therapeutics’s EPS for 12 months was -$3.08.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process